Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSF1R | P07333 | 12/20 | 0.44 |
| ▸ | GBA1 | P04062 | 2/20 | 0.42 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.40 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.40 |
| ▸ | CETP | P11597 | 1/20 | 0.39 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.38 |
| ▸ | SYK | P43405 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6800384 | 0.85 | GBA1 (0.46) | GBA1PIK3CDPIK3R1CETP | |
| SCHEMBL1486462 | 0.83 | MAOB (0.42) | — | |
| SCHEMBL3872009 | 0.81 | MAPT (0.51) | CSF1RGBA1 | |
| SCHEMBL3862493 | 0.77 | CSF1R (0.46) | CSF1R | |
| SCHEMBL5957142 | 0.75 | GBA1 (0.45) | GBA1PIK3CDPIK3R1CETP | |
| SCHEMBL3862490 | 0.72 | NLRP3 (0.47) | CSF1R | |
| SCHEMBL20475934 | 0.71 | GBA1 (0.39) | CSF1RGBA1 | |
| SCHEMBL30842221 | 0.71 | GBA1 (0.39) | CSF1RGBA1 | |
| SCHEMBL3861245 | 0.71 | CSF1R (0.46) | CSF1R | |
| SCHEMBL1486577 | 0.71 | F2 (0.47) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040147543-A1 | Aryl substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY | 2004-07-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040147543-A1 | Aryl substituted imidazoquinolines | IL2, IFNG, IRF3 | CSF1R 294/4885GBA1 1776/4885PIK3CD 2030/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.